hERGBoost:一种渐变增强模型,用于对hERG通道阻塞物的定量IC50预测
Myeong-Sang Yu1, Jingyu Lee1, Yunhyeok Lee1
1Department of Biomedical Engineering, Chung-Ang University, Seoul, Republic of Korea.
Computers in biology and medicine
|November 17, 2024
概括
我们开发了hERGBoost,一种机器学习模型,通过估计IC50值来预测候选药物心脏毒性. 这种工具有助于早期识别潜在的hERG通道阻断剂,以实现更安全的药物开发.
科学领域:
- 心血管药理学心血管药理学
- 计算化学是一种计算化学.
- 药物的发现和开发.
背景情况:
- 人类以太-a-go-go相关基因 (hERG) 通道在药物发现中至关重要.
- hERG通道阻断剂可能会导致严重的心脏毒性,需要早期识别.
- 现有的模型经常预测固定度 (10μM) 的心脏毒性,而不考虑不同的IC50值.
研究的目的:
- 开发一种精确的定量机器学习模型,用于预测与hERG通道阻塞相关的候选药物IC50值.
- 改善药物开发中的潜在心脏毒性化合物的早期识别.
主要方法:
- 开发了一种机器学习模型hERGBoost,该模型使用梯度增强算法.
- 在专门策划的数据集上训练模型,用于hERG通道阻断器预测.
- 使用外部验证指标 (R2和RMSE) 评估模型性能.
主要成果:
- 在预测候选药物的IC50方面,hERGBoost表现出卓越的准确性.
- 在外部验证中获得了0.394的R2得分和0.616的根平均平方误差.
- 在定性和定量评估方面显著优于以前的模型.
结论:
- 在预测hERG通道阻断器方面,hERGBoost代表了显著的进步.
- 该模型通过早期识别心脏毒性风险,为更安全的制药开发提供了宝贵的工具.
- 对于药物发现社区来说,hERGBoost模型和数据集是公开的.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
523
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
523
01:22Heart Failure Drugs: β-Blockers
319
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
707
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
707
01:22Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K